New hope for rare disease: rituximab trial in malawi
NCT ID NCT04585893
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase II trial tests the drug rituximab (Rituxan) as a first treatment for multicentric Castleman disease, a rare immune disorder, in 15 adults in Malawi. Some high-risk patients also receive etoposide. The study aims to see if rituximab is safe and works better than standard chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab (Rituxan) and etoposide for high-risk patients
- What this could lead to
- If successful, this could provide a safer, more effective first-line treatment for Castleman disease in Malawi, potentially replacing standard chemotherapy.
- What could go wrong
- This is a small, single-arm phase II trial with only 15 participants, so results may not be generalizable. Rituximab can cause infusion reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTICENTRIC CASTLEMAN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UNC Project, Kamuzu Central Hospital
Lilongwe, Malawi
More trials for these conditions
Other studies related to the condition(s) this trial covers.